News

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Names Dr. Allen R. Nissenson as Chief Medical Officer

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Names Dr. Allen Nissenson as Chief Medical Officer

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer.  Dr. Nissenson will join Sentien’s executive team and oversee the clinical development of Sentien’s lead product, SBI-101.  Dr. Nissenson serves as an Emeritus Professor of Medicine at the David Geffen School of Medicine at the University of California Los Angeles, Emeritus Chief Medical Officer of DaVita Kidney Care, and a member of the Board of Directors of Angion Biomedica Corp and Rockwell Medical, Inc. Read More >

Sentien Biotechnologies Names Richard Ganz as Executive Chairman

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Names Richard Ganz as Executive Chairman

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the appointment of Richard Ganz as Executive Chairman.  Mr. Ganz will continue to lead Sentien’s Board of Directors, a role he has filled for the past nine years, as well as work closely with CEO Brian Miller and Sentien’s management team. Read More >

By
In News
Posted

Sentien to Present SBI-101 Clinical Data in AKI at 2020 ASGCT Annual Meeting that Supports Expansion to COVID-19

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien to Present SBI-101 Clinical Data in AKI at 2020 American Society of Gene & Cell Therapy Annual Meeting that Supports Expansion to COVID-19

Sentien’s R&D team will present platform development and clinical data at the American Society of Gene & Cell Therapy Annual Meeting during virtual poster sessions.

Sentien’s SBI-101 clinical data in AKI patients shows immunomodulatory effects consistent with our therapeutic hypothesis and also applicable to COVID-19 patients.

Clinical Evidence for Immune Reprogramming with Extracorporeal Mesenchymal Stromal Cell Therapy

Ex-Vivo Cell Therapy Platform for Immune Reprogramming in Autoimmunity

Sentien VP of Operations Dr. Chris Gemmiti to speak at Phacilitate Leaders World & World Stem Cell Summit

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien VP of Operations Dr. Chris Gemmiti to speak at Phacilitate Leaders World & World Stem Cell Summit

On Jan 23rd at 1:50pm, Sentien VP of Operations Dr. Chris Gemmiti will be speaking about Sentien’s ex vivo allogeneic MSC therapy for the treatment of systemic, immune-mediated inflammation.

Sentien Co-Founder Dr. Biju Parekkadan to Speak at Cellular Therapeutics in Trauma and Critical Care Conference

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Co-Founder Dr. Biju Parekkadan to Speak at Cellular Therapeutics in Trauma and Critical Care Conference

Sentien Biotechnologies Scientific Co-Founder, Dr. Biju Parekkadan, will be speaking at the Cellular Therapeutics in Trauma and Critical Care conference on 12/13 at 4:05pm.  He will be discussing ex vivo MSC therapy for the treatment of systemic inflammatory disease.

Sentien Executives Dr. Chris Gemmiti and Dr. Rita Barcia to Speak at Cell & Gene Therapy Bioprocessing & Commercialization conference

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Executives Dr. Chris Gemmiti and Dr. Rita Barcia to Speak at Cell & Gene Therapy Bioprocessing & Commercialization Conference

Dr. Chris Gemmiti, VP Operations at Sentien, will be speaking on an Outsourcing vs. Insourcing panel on September 10, 2019.

Dr. Rita Barcia, Executive Director of R&D at Sentien, will be speaking on a Next Generation Therapies panel on September 12, 2019.

Sentien Co-Founder Dr. Biju Parekkadan to Speak at American Society of Gene & Cell Therapy Annual Meeting on 4/29

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Co-Founder Dr. Biju Parekkadan to Speak at American Society of Gene & Cell Therapy Annual Meeting on 4/29

Sentien Biotechnologies Scientific Co-Founder, Dr. Biju Parekkadan, will be speaking at the American Society of Gene & Cell Therapy Annual Meeting on April 29, 2019 in Washington, DC.  He will be discussing Reprogramming Human Immune Responses Using Ex Vivo MSC Bioreactor Therapy.

Load More